Portfoliotracker

Altimmune, Inc.

ALT · NASDAQGM · Healthcare Biotechnology 8/100 E

1,560 $
▼ −0,085 (−5,17 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:24
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score8 / 100 Market cap320 mil. $ P/E– Forward P/E-2,4 P/S7 810,4 P/B0,7 EV/EBITDA– Dividend yield– FCF yield-32,00 % EPS-0,71 $ Net margin0,0 % Return on equity-33,2 % Beta0,15 Debt / equity0,08
52-week range 1,50 to 6,44
3-month average volume4,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Employees
57
Country
United States
Fiscal year end
31. 12.
Data since
26. 5. 2017

Explore further

Similar companies VIRVKTX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account